Search hospitals > Pennsylvania > Pittsburgh
Children's Hospital of Pittsburgh of UPMC
Claim this profilePittsburgh, Pennsylvania 15224
Global Leader in Leukemia
Global Leader in Brain Tumor
Conducts research for Tumors
Conducts research for Recurrence
Conducts research for Lymphoma
907 reported clinical trials
83 medical researchers
Summary
Children's Hospital of Pittsburgh of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Leukemia, Brain Tumor, Tumors, Recurrence, Lymphoma and other specialties. Children's Hospital of Pittsburgh of UPMC is involved with conducting 907 clinical trials across 976 conditions. There are 83 research doctors associated with this hospital, such as Jean M. Tersak, Andrew Bukowinski, James Felker, MD, and Adam Olson.Area of expertise
1Leukemia
Global LeaderStage II
Philadelphia chromosome positive
NTRK1 positive
2Brain Tumor
Global LeaderBRAF positive
Stage IV
Stage II
Top PIs
Jean M. TersakChildren's Hospital of Pittsburgh of UPMC7 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
42 reported clinical trials
98 drugs studied
Andrew BukowinskiChildren's Hospital of Pittsburgh of UPMC8 years of reported clinical research
Studies Tumors
Studies Recurrence
24 reported clinical trials
38 drugs studied
James Felker, MDChildren's Hospital of Pittsburgh of UPMC4 years of reported clinical research
Expert in Brain Tumor
Studies Astrocytoma
16 reported clinical trials
27 drugs studied
Adam OlsonUPMC-Shadyside Hospital6 years of reported clinical research
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
15 reported clinical trials
52 drugs studied
Clinical Trials running at Children's Hospital of Pittsburgh of UPMC
Brain Tumor
Osteosarcoma
Acute Myeloid Leukemia
Diffuse Intrinsic Pontine Glioma
Medulloblastoma
Non-Hodgkin's Lymphoma
Tumors
Germ Cell Tumors
Recurrence
Ependymoma
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Hospital of Pittsburgh of UPMC?
Children's Hospital of Pittsburgh of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Leukemia, Brain Tumor, Tumors, Recurrence, Lymphoma and other specialties. Children's Hospital of Pittsburgh of UPMC is involved with conducting 907 clinical trials across 976 conditions. There are 83 research doctors associated with this hospital, such as Jean M. Tersak, Andrew Bukowinski, James Felker, MD, and Adam Olson.
Where is Children's Hospital of Pittsburgh of UPMC located?
The Children's Hospital of Pittsburgh of UPMC is located at 4401 Penn Ave, Pittsburgh, PA 15224, United States.
Who should I call to ask about financial aid or insurance network?
**Children's Hospital of Pittsburgh of UPMC Financial Assistance:**
- Contact the Business Office at 412-692-7600, available from 8 a.m. to 4 p.m., Monday through Friday.
**UPMC Western Maryland Insurance Hotline:**
- For insurance-related inquiries, call 240-964-8111.
What insurance does Children's Hospital of Pittsburgh of UPMC accept?
The Children's Hospital of Pittsburgh of UPMC accepts a wide range of health insurance plans. This includes commercial insurance plans such as Aetna, Capital Blue Cross, Cigna Health, and United HealthCare, among others. Government insurance plans accepted include Military insurances like VA and Tricare, Medicare plans such as Aetna Medicare Advantage and Highmark Freedom Blue, and Medicaid plans like Aetna Better Health and UPMC for You.
What awards or recognition has Children's Hospital of Pittsburgh of UPMC received?
UPMC Children's Hospital of Pittsburgh supports research through various grants, including:
- Pilot grants: $50,000 per year for two years.
- Trainee grants: $50,000 per year for two years.
- The Ghazi Lab has received research grants from the American Federation for Aging Research and the University of Pittsburgh.
- The Children's Neuroscience Institute offers annual Interdisciplinary Neuroscience Awards (INA) of up to $50,000, favoring projects that involve multi-omic platforms, induced pluripotent stem cell technology, bioinformatics, and molecular imaging approaches.